REGENERX (RGN) Reports Study Data on Tb4 Drug Candidates
More News related to RGN
- REGENERX (RGN) Reports Study Data on Tb4 Drug Candidates
- Promising Clinical Data with RegeneRx's Tb4 Drug Candidates Presented on Second Day of Thymosin Meeting
- Scientists Report Impressive Research Results with Tb4 on First Day of Thymosin Meeting
- Unusual 11 Mid-Day Movers 9/30: HOKU, ICCC, VSR, DSCO Higher; CIT, RGN, ICON, HX Lower
- Morning Movers 9/30: HOKU, ICCC, VSR, CFW, DSCO Higher; CIT, HX, RGN, ICON, APAB, RMTI Lower
REGENERX BIOPHARMACEUTICALS, INC. (Amex: RGN) reported on several clinical studies with Thymosin beta 4 (Tb4) presented the Second International Symposium on Thymosins in Health and Disease, in Catania, Italy.
More from Release
Related Categories
FDAStocks Mentioned
-0.01Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
